Journalartikel

Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study A Randomized Controlled Multicenter Trial


AutorenlistePetrak, Frank; Herpertz, Stephan; Albus, Christian; Hermanns, Norbert; Hiemke, Christoph; Hiller, Wolfgang; Kronfeld, Kai; Kruse, Johannes; Kulzer, Bernd; Ruckes, Christian; Zahn, Daniela; Mueller, Matthias J.

Jahr der Veröffentlichung2015

Seiten767-775

ZeitschriftDiabetes Care

Bandnummer38

Heftnummer5

ISSN0149-5992

eISSN1935-5548

DOI Linkhttps://doi.org/10.2337/dc14-1599

VerlagAmerican Diabetes Association


Abstract
OBJECTIVEThis study compared the long-term efficacy of a diabetes-specific cognitive behavioral group therapy (CBT) with sertraline in patients with diabetes and depression who initially responded to short-term depression treatment.RESEARCH DESIGN AND METHODSA randomized controlled single-blind trial was conducted in 70 secondary care centers across Germany comparing 12 weeks of CBT with sertraline in 251 patients with type 1 or 2 diabetes (mean HbA(1c) 9.3%, 78 mmol/mol) and major depression (Structured Clinical Interview for DSM-IV [SCID]). After 12 weeks, treatment responders (50% reduction Hamilton Depression Rating Scale [HAMD-17]) were included in the 1-year study phase where CBT patients were encouraged to use bibliotherapy and sertraline patients received continuous treatment. We analyzed differences for HbA(1c) (primary outcome) and reduction (HAMD-17) or remission (SCID) of depression from baseline to the 1-year follow-up using ANCOVA or logistic regression analysis.RESULTSAfter 12 weeks, 45.8% of patients responded to antidepressant treatment and were included in the 1-year study phase. Adjusted HbA(1c) mean score changes from baseline to the end of the long-term phase (-0.27, 95% CI -0.62 to 0.08) revealed no significant difference between interventions. Depression improved in both groups, with a significant advantage for sertraline (HAMD-17 change: -2.59, 95% CI 1.15-4.04, P < 0.05).CONCLUSIONSDepression improved under CBT and sertraline in patients with diabetes and depression, with a significant advantage for sertraline, but glycemic control remained unchanged. CBT and sertraline as single treatment are insufficient to treat secondary care diabetes patients with depression and poor glycemic control.



Zitierstile

Harvard-ZitierstilPetrak, F., Herpertz, S., Albus, C., Hermanns, N., Hiemke, C., Hiller, W., et al. (2015) Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study A Randomized Controlled Multicenter Trial, Diabetes Care, 38(5), pp. 767-775. https://doi.org/10.2337/dc14-1599

APA-ZitierstilPetrak, F., Herpertz, S., Albus, C., Hermanns, N., Hiemke, C., Hiller, W., Kronfeld, K., Kruse, J., Kulzer, B., Ruckes, C., Zahn, D., & Mueller, M. (2015). Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study A Randomized Controlled Multicenter Trial. Diabetes Care. 38(5), 767-775. https://doi.org/10.2337/dc14-1599



Schlagwörter


COLLABORATIVE CAREGLYCEMIC CONTROLMAJOR DEPRESSIONMELLITUS


Nachhaltigkeitsbezüge


Zuletzt aktualisiert 2025-21-05 um 18:35